RDY
Dr. Reddy's Laboratories Ltd.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · IN
$13.19
−0.53%Year over year
Reported trailing growth
- Revenue
- -0.4%
- EBITDA
- -37.7%
- EBIT
- -50.7%
- EPS
- -41.6%
- Free cash flow
- +4.9%
- Operating cash flow
- -22.0%
Forward estimates
Based on analyst estimates
- Revenue
- -18.9%
- EBITDA
- -1.4%
- EPS
- -9.4%
Three-year CAGR
- Revenue
- +12.9%
- EBITDA
- +3.8%
- EBIT
- -5.1%
- Net income
- +0.0%
- EPS
- -0.2%
- Free cash flow
- -7.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026